Treatment of AF Patient on Anticoagulant for ACS
For an AF patient on oral anticoagulation presenting with ACS, use a DOAC (preferably apixaban) plus clopidogrel, discontinue aspirin at or before discharge (within 1 week), and continue dual therapy (DOAC + clopidogrel) for 12 months. 1
Acute/Periprocedural Management
During the acute hospitalization and PCI procedure:
- Continue the oral anticoagulant throughout the procedure if already on a DOAC
- Add low-dose aspirin (81 mg) only during hospitalization
- Add a P2Y12 inhibitor (clopidogrel preferred over prasugrel/ticagrelor due to lower bleeding risk)
- Discontinue aspirin at or before discharge (within 1 week post-PCI) 1
The 2024 ESC guidelines explicitly recommend early cessation of aspirin (≤1 week) in uncomplicated PCI cases where thrombosis risk is low or bleeding risk is high 1. This represents a significant shift from older triple therapy approaches.
Choice of Anticoagulant
Switch to a DOAC if currently on warfarin - DOACs are strongly preferred over vitamin K antagonists because they:
- Reduce major bleeding by 31% (hazard ratio 0.69) 2
- Reduce death or hospitalization by 17% (hazard ratio 0.83) 2
- Provide similar protection against ischemic events 2
Apixaban is the preferred DOAC based on the AUGUSTUS trial, which demonstrated superior bleeding outcomes without compromising ischemic protection 2, 3. The most recent 2025 analysis of total events (not just first events) confirmed apixaban plus clopidogrel without aspirin minimizes overall bleeding while maintaining ischemic protection 3.
Duration of Therapy
For ACS patients:
- 0-1 week: Triple therapy (DOAC + aspirin + clopidogrel) during hospitalization only
- 1 week to 12 months: Dual therapy (DOAC + clopidogrel) 4, 1
- Beyond 12 months: DOAC monotherapy indefinitely 1
The 12-month duration of dual therapy for ACS is explicitly stated in the ACC guidelines 4. After 12 months, antiplatelet therapy should be discontinued as it provides no additional benefit and increases bleeding risk 1.
P2Y12 Inhibitor Selection
Use clopidogrel, not prasugrel or ticagrelor, unless there is very high ischemic risk. The AUGUSTUS trial data showed patients on high-potency P2Y12 inhibitors (prasugrel/ticagrelor) had significantly more recurrent bleeding events compared to clopidogrel 3. Clopidogrel is specifically recommended in both ACC and ESC guidelines for this indication 4, 1.
Critical Pitfalls to Avoid
Do not continue triple therapy beyond 1 week in uncomplicated cases - this dramatically increases bleeding without reducing ischemic events 1, 2
Do not use warfarin when a DOAC is available - warfarin increases bleeding by 45% compared to apixaban 2
Do not continue aspirin beyond discharge in most patients - aspirin doubles bleeding risk (rate ratio 2.14) without reducing ischemic events 3
Do not stop anticoagulation after 12 months - the AF stroke risk persists lifelong and requires indefinite anticoagulation 4, 1
Add a proton pump inhibitor when on dual or triple therapy to reduce GI bleeding 4
Evidence Strength
The recommendation is based on high-quality evidence from the AUGUSTUS randomized trial (2019) involving 4,614 patients 2, reinforced by the most recent 2025 total events analysis 3, and incorporated into both the 2024 ESC guidelines 1 and 2020 ACC expert consensus 4. All sources converge on the same strategy: DOAC (preferably apixaban) plus clopidogrel without aspirin after the initial hospitalization period.